Taylor Morrison Home Corporatio (TMHC) Stock Price & How to Invest

Taylor Morrison Home Corporation is one of the largest homebuilders in the United States, operating across roughly a dozen states in the West, Central, and East regions under the Taylor Morrison, Darling Homes, and Esplanade brands. Its offering spans entry-level, move-up, and luxury homes plus active-adult (55-plus) resort-style communities, and it has expanded into build-to-rent housing through its Yardly brand. The company also runs a Financial Services segment covering mortgage origination, title, and insurance services that attaches financing to its home closings. In full-year 2025 it delivered about 12,997 homes on roughly $7.76 billion of home closings revenue and around $783 million of net income (about $7.77 per diluted share).

The investment picture is classic housing cyclicality with a diversification tilt. Revenue and margins expand when rates are manageable and buyers can afford homes, and compress when affordability tightens. Q1 2026 showed the softer side: total revenue fell to about $1.39 billion from roughly $1.90 billion a year earlier, home closings dropped to 2,268 units, net income fell to about $99 million ($1.01 per diluted share), and home closings gross margin narrowed to 20.0% as the company leaned on discounts and financing incentives. Against that backdrop TMHC carries a solid balance sheet and returns meaningful cash through buybacks (about 2.5 million shares repurchased for roughly $150 million in Q1 2026), which is much of the equity story at a low earnings multiple.

Taylor Morrison is highly cyclical and its results hinge on factors outside its control. Elevated mortgage rates and stretched affordability directly suppress demand, average selling prices, and gross margins, as the Q1 2026 drop to a 20.0% home closings margin showed. Management has pointed to tariffs, inflation, and geopolitical uncertainty as additional drags on buyer confidence, and rising cancellation rates plus a shrinking backlog signal softer forward demand. Margin-eroding financing incentives and rate buydowns are common in slower markets, and rising land, labor, and materials costs squeeze profitability. Because much of the equity return comes from buybacks, a downturn that forces cash to be conserved would remove a key support for the stock.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Taylor Morrison Home Corporatio's investor relations page or your broker.

• Revenue (TTM): ~$7-8B total revenue
• Net income (2025): ~$783M
• 2025 diluted EPS: ~$7.77 (adjusted ~$8.24)
• Q1 2026 EPS: ~$1.01 (down from ~$2.07)
• Market cap: ~$5-6B
• Trailing P/E: ~8x

Taylor Morrison trades at roughly 8 times trailing earnings, a low multiple typical of cyclical homebuilders where the market prices in the risk of a downturn. The 2025 record of about $7.76 billion in home closings revenue and $783 million of net income is giving way to softer 2026 comparisons, with Q1 revenue, closings, and margins all down year over year. The company pays no meaningful dividend and returns cash mainly through buybacks, so the low P/E reflects cycle risk rather than a simple valuation signal.

There are three common ways to get TMHC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so TMHC sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where TMHC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

TMHC is a diversified, buyback-heavy homebuilder trading at a low earnings multiple, so the story is housing cyclicality and capital returns more than secular growth.

Whether TMHC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is TMHC a buy?, and where the stock could go from here in the TMHC stock forecast.

For income investors, whether TMHC pays a dividend and how the payout looks is covered in does TMHC pay a dividend?